{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:32:48Z","timestamp":1783960368826,"version":"3.55.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Following systemically administered adeno-associated virus gene therapy, vector particles are widely distributed, raising concerns about horizontal or germline vector transmission. Characterization of biodistribution and kinetics of vector DNA in body fluids can address these concerns and provide insights into vector behavior in accessible samples. We investigated biodistribution and vector shedding profile of valoctocogene roxaparvovec in men with severe hemophilia A enrolled in the phase 3 GENEr8-1 trial. Participants (n\u00a0=\u00a0134) received a single 6\u00a0\u00d7 1013 vector genome (vg)\/kg infusion and were assessed over 3 years. Vector DNA was measured using 4 different assays. Total vector DNA was evaluated in blood, saliva, stool, semen, and urine by quantitative polymerase chain reaction (qPCR). Encapsidated vector DNA was measured in plasma and semen with immunocapture-based qPCR. Contiguity of vgs and assembly of inverted terminal repeat fusions were measured in whole blood and peripheral blood mononuclear cells (PBMCs) using multicolor digital PCR. Median peak vector DNA levels observed 1 to 8\u00a0days after dosing were highest in blood, followed by saliva, semen, stool, and urine. Concentrations declined steadily. Encapsidated vector DNA cleared faster than total vector DNA, achieving clearance by \u226412\u00a0weeks in plasma and semen. Predominant vector genome forms transitioned from noncontiguous to full-length over time in whole blood and PBMCs, indicating formation of stable circularized episomes within nucleated cells. The replication-incompetent nature of valoctocogene roxaparvovec, coupled with steady clearance of total and encapsidated vector DNA from shedding matrices, indicates transmission risk is low. This trial was registered at www.ClinicalTrials.gov as #NCT03370913.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013150","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T20:27:32Z","timestamp":1721334452000},"page":"4606-4615","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A"],"prefix":"10.1182","volume":"8","author":[{"given":"Suresh","family":"Agarwal","sequence":"first","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Sandza","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-7013","authenticated-orcid":false,"given":"Kristin","family":"Obrochta Moss","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Vora","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-6697","authenticated-orcid":false,"given":"Alisa","family":"Bowen","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna","family":"Bunch","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Holcomb","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Robinson","sequence":"additional","affiliation":[{"name":"2Late Clinical Development, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kala","family":"Jayaram","sequence":"additional","affiliation":[{"name":"3Pharmacovigilance, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-1815","authenticated-orcid":false,"given":"Chris B.","family":"Russell","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Zoog","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vettermann","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Henshaw","sequence":"additional","affiliation":[{"name":"1Translational Sciences, BioMarin Pharmaceutical Inc, Novato, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"suppl 6","key":"2024091012553434000_bib1","first-page":"1","article-title":"","volume":"26","author":"Srivastava","year":"2020","journal-title":"WFH guidelines for the management of hemophilia"},{"key":"2024091012553434000_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24(suppl 6)","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"key":"2024091012553434000_bib3","first-page":"S3","article-title":"Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia","volume":"90(suppl 2)","author":"Witkop","year":"2015","journal-title":"Am J Hematol"},{"issue":"16","key":"2024091012553434000_bib4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2024091012553434000_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2024091012553434000_bib6","first-page":"1687","article-title":"Patient and parent preferences for characteristics of prophylactic treatment in hemophilia","volume":"9","author":"Furlan","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"2024091012553434000_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14304","article-title":"Patients' and parents' satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study","volume":"27","author":"Park","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"2024091012553434000_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40271-019-00395-6","article-title":"Patient perspectives on novel treatments in haemophilia: a qualitative study","volume":"13","author":"van Balen","year":"2020","journal-title":"Patient"},{"issue":"2","key":"2024091012553434000_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"issue":"4","key":"2024091012553434000_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"issue":"26","key":"2024091012553434000_bib11","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024091012553434000_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024091012553434000_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"issue":"11","key":"2024091012553434000_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024091012553434000_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024091012553434000_bib16","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024091012553434000_bib17","unstructured":"US Food and Drug Administration\n          . Long term follow-up after administration of human gene therapy products guidance for industry. 2020. Accessed 7 July 2023. https:\/\/www.fda.gov\/media\/113768\/download."},{"key":"2024091012553434000_bib18","unstructured":"US Food and Drug Administration\n          . S12 Nonclinical biodistribution considerations for gene therapy products guidance for industry. 2023. Accessed 7 July 2023. https:\/\/www.fda.gov\/media\/167605\/download."},{"key":"2024091012553434000_bib19","unstructured":"US Food and Drug Administration\n          . Design and analysis of shedding studies for virus or bacteria based gene therapy and oncolytic products. 2015. Accessed 12 July 2023. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Design-and-Analysis-of-Shedding-Studies-for-Virus-or-Bacteria-Based-Gene-Therapy-and-Oncolytic-Products--Guidance-for-Industry.pdf."},{"issue":"1-2","key":"2024091012553434000_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41434-021-00287-1","article-title":"Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer","volume":"29","author":"Sandza","year":"2022","journal-title":"Gene Ther"},{"key":"2024091012553434000_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semcdb.2016.04.009","article-title":"Spermatogenesis in humans and its affecting factors","volume":"59","author":"Neto","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"2024091012553434000_bib22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu Rev Genet"},{"issue":"10","key":"2024091012553434000_bib23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/jgm.1096","article-title":"An inventory of shedding data from clinical gene therapy trials","volume":"9","author":"Schenk-Braat","year":"2007","journal-title":"J\u00a0Gene Med"},{"issue":"9","key":"2024091012553434000_bib24","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024091012553434000_bib25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2019-129786","article-title":"Clearance of vector DNA following systemic administration of AAV5-hFIX or AAV5-hFIX Paudua in patients with severe or moderate-severe hemophilia B","volume":"134","author":"Sawyer","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2024091012553434000_bib26","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1089\/104303401753153956","article-title":"A\u00a0phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease","volume":"12","author":"Aitken","year":"2001","journal-title":"Hum Gen Ther"},{"issue":"suppl 1","key":"2024091012553434000_bib27","doi-asserted-by":"crossref","first-page":"10662","DOI":"10.1182\/blood-2022-159027","article-title":"Rapid clearance of vector following AAV-mediated FVIII gene transfer in phase I\/II trial of SPK-8011 in people with hemophilia A","volume":"140","author":"Tran","year":"2022","journal-title":"Blood"},{"issue":"7-8","key":"2024091012553434000_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41434-022-00318-5","article-title":"Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy","volume":"30","author":"Fonck","year":"2023","journal-title":"Gene Ther"},{"key":"2024091012553434000_bib29","unstructured":"ROCTAVIAN (valoctocogene roxaparvovec)\n          . Prescribing information. BioMarin Pharmaceutical Inc. 2023. Accessed 7 July 2023. https:\/\/www.fda.gov\/media\/169937\/download."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4606\/2241254\/blooda_adv-2024-013150-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4606\/2241254\/blooda_adv-2024-013150-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:56:11Z","timestamp":1725972971000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4606\/517075\/Blood-biodistribution-and-vector-shedding-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013150","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}